OpenAI partners with Novo Nordisk to accelerate drug discovery and delivery
Artificial intelligence powerhouse OpenAI Group PBC is lending its expertise to Novo Nordisk A/S in a new partnership announced today that aims to accelerate research in the pharmaceutical industry. The sweeping collaboration will see OpenAI’s intelligent agents embedded across t...
SiliconANGLE
Source

Generated insight by OnAirToday AI
This partnership signifies a major leap in applying advanced AI to the intricate and time-consuming process of drug discovery. By integrating OpenAI's capabilities, Novo Nordisk aims to significantly speed up the identification and development of new therapies, potentially leading to faster patient access to life-saving medications.
Get the day's AI news in one short email. Free.
Comments
Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.